TAFERO-TENOFOVIR-ALAFENOMIDE-25MG

Tafero 25 MG

Drug profile for Tafero tablet:

Tafero tablets are primarily used in hepatitis infection condition, is in chronic stage.

Tafero tablets are only used by the patients who are having a valid prescription

Tafero 25MG tablets are containing an anti-viral agent known as Tenofovir Alafenamide which may not cure the infection but may suppress the growth of virus.


Trade name: Tafero

Active component: Tenofovir Alafenamide

Strength: 25mg

Mfg: Hetero pharmaceuticals

Pack: 30 tablets in a container

Category: Anti-hepaciviral activity


Prescribing information of Tafero

The most frequently used anti-viral agent like Tenofovir Alafenamide is primarily indicated for the treatment of chronic hepatitis B viral infection occurred in adults patient with compensated liver damage.

Mechanism of Tafero

Tafero worked in the body by some component incorporates;

For the most part Tafero  25mgcontaining tenofovir Alafenamide is a prodrug which is changed over into dynamic frame in-vivo

Tenofovir Alafenamide has cell penetrability property which is lipophilic in nature, infiltrates into hepatocytes by latent dissemination strategy and additionally by hepatic return transporters OATP1B1 and OATP1B3

In-vivo, tenofovir Alafenamide is changed into tenofovir a parent compound by experiencing hydrolysis with the chemical carboxylesterase 1 which is happen in hepatocytes cell

This dynamic frame tenofovir is phosphorylated into tenofovir diphosphate by cell kinase compounds

TAF has pharmacologically dynamic compound known as tenofovir diphosphate which is in charge of viral multiplication denial by means of imbuing into infection DNA with the assistance of turnaround transcriptase chemical which causes viral DNA chain end

Absorption:

Maximum plasma concentration time of TAF 0.48 hours

Distribution:

TAF is largely bound to human plasma protein at 80%

Protein binding data occurs in vivo

The blood plasma ratio of TAF is 1.0

Metabolism:

The metabolism of TAF occurs with the help of;

Carboxyl esterase 1

Cathepsin A

CYP3A

TAFERO 25MG

Excretion:

Nearly 80% of TAF get metabolized and reaches its half life at 0.51 hour

<1% of metabolite released through urine

31.7% excreted via feces

When to take the Tafero tablets

Tafero 25mg tablets should be taken with food

Dosage regimens of Tafero

Before initiate the treatment with Tafero tablets, patients must be investigate whether they are suspected with HIV 1 infection or not.

The suggested dosage of Tafero is 25mg should be administered as a single dose.

In both mild to moderate liver and kidney impaired patients, dosage adjustment should not be allowed; whereas severe conditions, Tafero not recommended.

Tafero caused side effects

The most serious adverse effects;

Serious exacerbation of hepatitis B infection

Out breaking or worsening of renal damage

Lactic acidosis

Hepatomegaly with steatosis

Common side effects;

Fatigue

Headache

Cough

Back pain

Nausea

Abdominal pain

Loss of bone mineral density

Glycosuria

Increase in lipase & amylase

Increasing in serum lipids

Drug- drug interaction of Tafero

Tafero tablets with P-gp or BCRP inhibiting drugs, causes variation in absorption of TAF; this may leads to adverse effects.

Tafero tablets with P gp or BCRP inducing drugs causes depletion of absorption of TAF leads to increasing the concentration of TAF

Tafero25mg tablets with renal function reducing drugs may leads to increasing the concentration and causes serious adverse effects

Tafero tablet combined with anti-convulsants leads to decreasing the effect of concentration of TAF

Tafero tablet combined with anti-mycobacterials causes reducing the effect of concentration of TAF

Tafero tablets concomitant use of herbal product like st, John’s wort, causes decreasing the TAF concentration.

Food drug interaction of Tafero;

Minor food drug interaction may occur; alcohol containing food items should not be suggested.

Consult with physician about the dietary.

Possible contraindications of Tafero

No specific contraindication occurs, if some patients may contraindicate to TAF causes anaphylactic reactions.

Safety measures:

Aggravation of hepatitis B infection: Check the patient history before starting the treatment

Exposure of advancement of HIV-1 resistance: Due to this condition, Tafero tablets are not suggested for HIV-1 infections

New commencement of renal damage: To avoid concomitant use of Tafero with renal function depleting drugs

Lactic acidosis or hepatomegaly with steatosis: Stop the therapy with Tafero

Pregnancy and lactation:

Tafero tablets are probably used in pregnancy conditions, only after knowing the risk of the product associated to fetus.

Breast feeding should not be suggested.

Storage and handling:

Tafero 25mg  tablet container should be kept at below 30oC

Protect the container from heat, moisture & heat

Missed dose:

In case of missed dose, get advice from medical practitioner and their instruction; otherwise avoid the missed dose and follow the regular schedule.

Over dosage:

If over dosage occurs during the therapy;

Provide the patients with supportive measures

Monitor the signs & symptoms

Hemodialysis is done, to eliminate the TAF content with the range of 54%.

CONTACT US:

PHONE NO:+919940472902

EMAIL:millionhealthpharmaceuticals@gmail.com

WEBSITE URL:https://pillsbag.com/products/tafero-25-mg